SCHEDULE 13G/A 0000902664-24-006531 0001633313 XXXXXXXX LIVE 1 Common Stock, par value $0.0001 per share 12/31/2025 0001599901 Avidity Biosciences, Inc. 05370A108 3020 CALLAN ROAD SAN DIEGO CA 92121 Rule 13d-1(b) Avoro Capital Advisors LLC b DE 8515792.00 0.00 8515792.00 0.00 8515792.00 N 5.54 IA OO Includes 3,060,792 shares of Common Stock issuable upon exercise of pre-funded warrants. Behzad Aghazadeh b X1 8515792.00 0.00 8515792.00 0.00 8515792.00 N 5.54 HC IN Includes 3,060,792 shares of Common Stock issuable upon exercise of pre-funded warrants. Avidity Biosciences, Inc. 3020 Callan Road, San Diego, CA 92121 This statement is filed by: (i) Avoro Capital Advisors LLC, a Delaware limited liability company ("Avoro"), which provides investment advisory and management services and has acquired the shares of common stock, par value $0.0001 per share ("Common Stock") of Avidity Biosciences, Inc., a Delaware corporation (the "Company"), solely for investment purposes on behalf of Avoro Life Sciences Fund LLC, a Delaware limited liability company, and (ii) Behzad Aghazadeh ("Dr. Aghazadeh," and together with Avoro, the "Reporting Persons"), who serves as the portfolio manager and controlling person of Avoro. The filing of this statement should not be construed as an admission that any Reporting Person is, for purposes of Section 13 of the Act, the beneficial owner of the securities reported herein. The address of the business office of each of the Reporting Persons is 110 Greene Street, Suite 800, New York, NY 10012. Avoro is a Delaware limited liability company. Dr. Aghazadeh is a United States citizen. N IA HC The information required by Item 4(a) is set forth in Row 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The percentage set forth in this Schedule 13G is calculated based upon an aggregate of 150,675,742 shares of Common Stock outstanding as of October 31, 2025, as reported in the Company's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2025, filed with the Securities and Exchange Commission on November 10, 2025, and includes shares of Common Stock issuable upon exercise of pre-funded warrants. 5.54% The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Y N See Item 2(a). Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Avoro Capital Advisors LLC /s/ Scott Epstein 02/17/2026 Behzad Aghazadeh /s/ Behzad Aghazadeh 02/17/2026